Florida State University Research Foundation, Inc.

Emory University

Children's Healthcare of Atlanta, Inc.

Vaxart, Inc.

Richard K Plemper

Dennis C Liotta

Michael G Natchus

James P Snyder

Aiming Sun

John Vernachio

Elyse Bourque

Eddy Lee

Edgars Jecs

Zackery Will Dentmon

Stephen Pelly

Dan Yan

John M Ndungu

Jeong-Joong Yoon

Veronika Von Messling

Julien Sourimant

Robert Wilson

Disclosed herein are compounds having antiviral activity, and, in particular, an inhibitory activity on the replication of Respiratory Syncytial Virus (RSV). Druggable target sites, including Px, in the RSV N protein are disclosed, as well as compounds targeting Px. The compounds can be used to treat patients with RSV infection.

Inhibitors of RSV replication and applications thereof

Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof.

Heterocyclic derivatives for the treatment of RSV

Bicyclic fused pyrazole derivatives for the treatment of RSV

Disclosed herein is a strategy for the engineering of recombinant vaccines against major human and animal pathogens of the paramyxovirus family. Also disclosed are recombinant virus able to replicate without being pathogenic. Also disclosed is a method of immunizing a subject against infection with a that involves administering to the subject a recombinant vaccine disclosed herein.

Tunable vaccine platform against pathogens of the paramyxovirus family

An RSV reporter strain that can be used for high-throughput drug discovery is disclosed. Also disclosed is a recombinant RSV vector that contains an RSV genome encoding the disclosed RSV reporter strain operably linked to an expression control sequence. Also disclosed is an infectious RSV virion produce by expression of the disclosed recombinant RSV vector in a host cell. Also disclosed is a recombinant nucleic acid that comprises an RSV F protein having an escape mutation operably linked to a heterologous expression control sequence. Also disclosed are methods of screening for antiviral agents using the disclosed RSV reporter strains.

Recombinant RSV reporter virus

This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: or salt, prodrug, or ester thereof wherein X, Y, and Rand Rto Rare described herein.

Myxovirus therapeutics, compounds, and uses related thereto

This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and Rand Rto Rare described herein. 

This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising 2-((benzo[d]imidazol-2-yl)thio)-N-phenylpropanamide derivatives, N-phenyl-2-((1-phenyl-benzo[d]imidazol-2-yl)thio)propanamide derivatives, or 2-((benzo[d]imidazol-2-yl)thio)-N-(2-chloro-4-methylphenyl)propanamide derivatives. The derivatives may be substituted with one or more substituents. Typically, the pharmaceutical composition comprises a compound of Formula (I), or salt, prodrug, or ester thereof wherein X, Y, and R1 to R7 are described herein. 

Imidazolyl amide compounds and uses related thereto

Embodiments of the present disclosure include methods for identifying a compound or compounds useful as therapeutic agents in the treatment of paramyxovirus infections, compounds for the treatment of measles, and high throughput screening methods for identifying compounds capable of inhibiting the proliferation of a paramyxovirus.

Growing community of inventors

Decatur, GA, United States of America

Richard K Plemper